Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Credit: Image generated by VentureBeat with FLUX-pro-1.1 Without data, enterprise AI isn't going to be successful. Getting all the data in one place and having the right type of data tools, including ...

A TechRadar article noted that nearly 90% of enterprise information (documents, emails, videos) lies dormant in unstructured systems. This "dark data" isn't just neglected; it's a liability. GenAI ...

I co-created Graph Neural Networks while at Stanford. I recognized early on that this technology was incredibly powerful. Every data point, every observation, every piece of knowledge doesn’t exist in ...

Data‑analysis workflow. Experimental and computational datasets are unified; crystal‑structure graphs, deep learning, and dimensionality reduction yield the materials map. Selecting the right material ...

The last time I wrote about Recursion Pharmaceuticals (RXRX), it was with respect to a Seeking Alpha article entitled "Recursion: CDK7 Differentiation Is Initially Paying Off." With respect to this ...

Forbes contributors publish independent expert analyses and insights. I track enterprise software application development & data management. Jul 03, 2025, 10:43am EDT Business 3d tablet virtual growth ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. MIT and Recursion have released Boltz-2, the first ...

Neo4j Inc. today announced a new serverless offering that dramatically simplifies the deployment of its graph database offering, making it easier to use with artificial intelligence applications. Most ...